CRISPR Therapeutics shared new results showing hopeful responses from patients using zugocabtagene geleucel for tough autoimmune diseases.

Nov 8, 2026, 3:10 PM ETTrialRead the original at globenewswire.com

Good for CRSP

CRISPR Therapeutics reported responses in its early trial, including all 9 people with muscle disease. The findings support the treatment's promise, though only 21 people were treated across 3 diseases and no lupus response figures were given.

CRSP · CRISPR Therapeutics

AI read · Good for CRSP

The AI's read

The treatment showed responses in both reported disease groups, and the company reported no severe immune-related problems described in the update. These are encouraging signs, but the study is still early, covers only 21 people across 3 diseases, and gives no response figures for lupus.

Get alerts for CRSP

Follow CRISPR Therapeutics (CRSP) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CRSP

Free on the App Store and Google Play, or on the web.